Cyclacel’s CYC065 Succeeds in Lung Cancer Study (CYCC)

Share it with your friends Like

Thanks! Share it with your friends!


Cyclacel’s CYC065 Succeeds in Lung Cancer Study (CYCC)
The data was presented by independent investigators at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D. C.
The data demonstrates that the drug was successful in substantially restraining the growth of cancer, triggering normal and controlled death of cells (called apoptosis), and inducing anaphase catastrophe, a mechanism
that specifically targets tumor cells with certain features, in rodents and human lung cancer cells which have high metastatic potential.
The drug also markedly restrained migration and invasion of lung cancer cells
and affected distinctive pathways involved in DNA damage response, apoptosis, cell cycle regulation and cell migration.
The data indicates the potential of CYC065 to selectively target key molecular features of cancers, which can be key in fighting off cancer cells.
Cyclacel Pharmaceuticals Inc. (CYCC) announced positive pre-clinical data for its cancer drug candidate, CYC065.
“This study adds to the growing evidence of the value of CDK inhibition as an approach to
treating cancer,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.


Write a comment